Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy

Oncoimmunology. 2022 Nov 1;11(1):2141978. doi: 10.1080/2162402X.2022.2141978. eCollection 2022.

Abstract

The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selectively eliminate G12Ci-resistant cells.

Keywords: KRAS-G12C; bispecific T cell engagers.

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Cell Line, Tumor
  • Humans
  • Lung Neoplasms* / drug therapy
  • Mutation
  • Proto-Oncogene Proteins p21(ras) / genetics
  • T-Lymphocytes

Substances

  • Proto-Oncogene Proteins p21(ras)
  • KRAS protein, human